EIF4A2 interacts with the membrane protein of transmissible gastroenteritis coronavirus and plays a role in virus replication

Song, Zhenhui; Yang, Yang; Wang, Li; Wang, Kai; Ran, Ling; Xie, Yong; Huang, LeiShi; Zhou, Yang; Yuan, Peng; Yu, Qiuhan

doi:10.1016/j.rvsc.2018.12.005

Cited by 11 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Relatively few genes were specifically upregulated in COVID-19 patients compared to both other viral and non-viral ARIs. These included TRO , which encodes a membrane-bound cell adhesion molecule; WDR74 , which plays a role in rRNA processing and associates with the RNA helicase MTR4 28 ; EIF4A2 , a translation initiation factor that has been shown to interact with other coronaviruses as well as HIV 29 , 30 ; and FAM83A , which is involved in epidermal growth factor receptor (EGFR) signaling 31 (Supplementary Fig. 3c ).…”

Section: Resultsmentioning

confidence: 99%

Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses

et al. 2020

View full text Add to dashboard Cite

SARS-CoV-2 infection is characterized by peak viral load in the upper airway prior to or at the time of symptom onset, an unusual feature that has enabled widespread transmission of the virus and precipitated a global pandemic. How SARS-CoV-2 is able to achieve high titer in the absence of symptoms remains unclear. Here, we examine the upper airway host transcriptional response in patients with COVID-19 (n = 93), other viral (n = 41) or non-viral (n = 100) acute respiratory illnesses (ARIs). Compared with other viral ARIs, COVID-19 is characterized by a pronounced interferon response but attenuated activation of other innate immune pathways, including toll-like receptor, interleukin and chemokine signaling. The IL-1 and NLRP3 inflammasome pathways are markedly less responsive to SARS-CoV-2, commensurate with a signature of diminished neutrophil and macrophage recruitment. This pattern resembles previously described distinctions between symptomatic and asymptomatic viral infections and may partly explain the propensity for pre-symptomatic transmission in COVID-19. We further use machine learning to build 27-, 10- and 3-gene classifiers that differentiate COVID-19 from other ARIs with AUROCs of 0.981, 0.954 and 0.885, respectively. Classifier performance is stable across a wide range of viral load, suggesting utility in mitigating false positive or false negative results of direct SARS-CoV-2 tests.

show abstract

Section: Resultsmentioning

confidence: 99%

Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses

et al. 2020

View full text Add to dashboard Cite

show abstract

“…16,17 The M protein plays a pivotal role in virus assembly, budding, and replication of virus particles in the host cells. 18 SARS-CoV-2 is transmitted quickly and causes a considerable fatality rate, so that World Health Organization (WHO) reported over 14,562 550 cases globally and at least 9898 deaths because of this disease until July 21, 2020. 19 It can be controlled when medical resources are sufficient but, there is currently no vaccine or approved treatment for this disease.…”

Section: Introductionmentioning

confidence: 99%

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Yazdani¹,

Rafiei²,

Yazdani³

et al. 2020

IDR

View full text Add to dashboard Cite

Background: To date, no specific vaccine or drug has been proven to be effective against SARS-CoV-2 infection. Therefore, we implemented an immunoinformatic approach to design an efficient multi-epitopes vaccine against SARS-CoV-2. Results: The designed-vaccine construct consists of several immunodominant epitopes from structural proteins of spike, nucleocapsid, membrane, and envelope. These peptides promote cellular and humoral immunity and interferon-gamma responses. Also, these epitopes have a high antigenic capacity and are not likely to cause allergies. To enhance the vaccine immunogenicity, we used three potent adjuvants: Flagellin of Salmonella enterica subsp. enterica serovar Dublin, a driven peptide from high mobility group box 1 as HP-91, and human beta-defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. The tertiary structure of the vaccine protein was predicted and refined by Phyre2 and Galaxi refine and validated using RAMPAGE and ERRAT. Results of ElliPro showed 246 sresidues from vaccine might be conformational B-cell epitopes. Docking of the vaccine with toll-like receptors (TLR) 3, 5, 8, and angiotensinconverting enzyme 2 approved an appropriate interaction between the vaccine and receptors. Prediction of mRNA secondary structure and in silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli. Conclusion: Our results demonstrated that the multi-epitope vaccine might be potentially antigenic and induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, it has a high-quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli .

show abstract

“…protein E has an important role in the assembly of the viral genome[16, 17]. The M protein plays a pivotal role in virus assembly,budding and replication of virus particles in the host cells[18].…”

Section: Introductionmentioning

confidence: 99%

Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis

Yazdani

Rafiei

Yazdani

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To date, no specific vaccine or drug has been proven to be effective for SARS-CoV-2 infection. Therefore, we implemented immunoinformatics approach to design an efficient multi-epitopes vaccine against SARS-CoV-2.Results: The designed vaccine construct has several immunodominant epitopes from structural proteins of Spike, Nucleocapsid, Membrane and Envelope. These peptides promote cellular and humoral immunity and Interferon gamma responses. In addition, these epitopes have antigenicity ability and no allergenicity probability. To enhance the vaccine immunogenicity, we used three potent adjuvants; Flagellin, a driven peptide from high mobility group box 1 as HP-91 and human beta defensin 3 protein. The physicochemical and immunological properties of the vaccine structure were evaluated. Tertiary structure of the vaccine protein was predicted and refined by I-Tasser and galaxi refine and validated using Rampage and ERRAT. Results of Ellipro showed 242 residues from vaccine might be conformational B cell epitopes. Docking of vaccine with Toll-Like Receptors 3, 5 and 8 proved an appropriate interaction between the vaccine and receptor proteins. In silico cloning demonstrated that the vaccine can be efficiently expressed in Escherichia coli.Conclusions: The designed multi epitope vaccine is potentially antigenic in nature and has the ability to induce humoral and cellular immune responses against SARS-CoV-2. This vaccine can interact appropriately with the TLR3, 5, and 8. Also, this vaccine has high quality structure and suitable characteristics such as high stability and potential for expression in Escherichia coli.

show abstract

EIF4A2 interacts with the membrane protein of transmissible gastroenteritis coronavirus and plays a role in virus replication

Cited by 11 publications

References 26 publications

Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses

Upper airway gene expression reveals suppressed immune responses to SARS-CoV-2 compared with other respiratory viruses

<p>Design an Efficient Multi-Epitope Peptide Vaccine Candidate Against SARS-CoV-2: An in silico Analysis</p>

Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis

Contact Info

Product

Resources

About